StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Stock analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, April 15th.

Can-Fite BioPharma Price Performance

CANF stock opened at $1.18 on Thursday. The company has a 50-day moving average of $1.53 and a two-hundred day moving average of $1.75. The stock has a market capitalization of $4.18 million, a price-to-earnings ratio of -0.66 and a beta of 1.37. Can-Fite BioPharma has a 52-week low of $1.14 and a 52-week high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers boosted its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.